subject: Global Data: Polycystic Ovarian Syndrome - Pipeline Assessment and Market Forecasts [print this page] Global Data: Polycystic Ovarian Syndrome - Pipeline Assessment and Market Forecasts
GlobalData, the industry analysis specialist, has released its new report, "Polycystic Ovarian Syndrome - Pipeline Assessment and Market Forecasts to 2017". The report is an essential source of information and analysis on the global Polycystic Ovarian Syndrome (PCOS) market. The report identifies the key trends shaping and driving the global PCOS market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global PCOS sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts. GlobalData estimated the Polycystic Ovarian Syndrome (PCOS) market to be worth $706m in 2009 and projects it to grow at a CAGR of 0.6% to reach $742m in 2017. The market is expected to decrease by 30.1% from $805m in 2011 to $563m in 2012. The decrease in the market will be due to the expiry of Letrozole's patent in the year 2011.The market will gain pace from 2013 and will grow to $742m in 2017. The slow growth rate is largely because of the under diagnosis of this syndrome. However, the market is driven by an increasing prevalence rate, diagnosis rate and treatment seeking rate. The rise in the prescription population will contribute to the growth of the PCOS market. Due to the presence of a large number of generic products and a weak pipeline, this market will not grow at a significant rate
* The report provides information on the key drivers and challenges of the Polycystic Ovarian Syndrome (PCOS) market. Its scope includes:
* Annualized global PCOS market revenues data from 2001 to 2009, forecast for eight years to 2017.
* Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as estrogen antagonists, female gamete inhibitor, insulin secretion inhibitor, HMG CoA inhibitor, Gastric and pancreatic lipase inhibitor and fats break down inhibitor.
* Analysis of the current and future competition in the global PCOS market. Key market players covered are Merck KGaA, Catalysis SL and Amylin Pharma.
* Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
* Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the PCOS therapeutics market
GlobalData is a UK-based company with presence across North America, Europe and Asia Pacific and has a broad product offering that ranges from interactive databases, reports and custom solutions. It is a comprehensive source of insights and analysis with coverage including oil & gas, power, alternative energy, nuclear power, petrochemicals, medical equipment and healthcare industries.
Visit our Report Store
http://www.globaldata.com/reportstore/
welcome to Insurances.net (https://www.insurances.net)
